RxDoctor Payments Data

Parisa Dudley

Optometrist · Birmingham, ALNPI 1063505097

Payments from drug & device makers

$489in general payments, 2019–2025

Across 16 payments — averaging $30.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Harrow Eye, LLC$164
  • NEW World Medical,inc.$128
  • Oyster Point Pharma, Inc.$72
  • Sun Pharmaceutical Industries Inc.$44
  • Tarsus Pharmaceuticals, Inc.$34
  • AbbVie$32
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$489100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$489 in reported general payments places this provider in the 35th percentile of 749 optometrist providers in Alabama.

See all optometrist providers in Alabama

Medicare billing

Part B allowed, 2024
$78,687
Medicare patients
510
Services billed
967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine30$33,262
Cyclosporine14$12,939
XiidraLifitegrast12$9,549
Latanoprost334$4,612
ErythromycinErythromycin Base183$2,078
Epinastine Hcl29$1,603
Tobramycin-DexamethasoneTobramycin/Dexamethasone29$1,241
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat55$1,040
Prednisolone Acetate13$732
Ketorolac Tromethamine22$489
Dorzolamide Hcl18$434
Timolol Maleate27$391
Ofloxacin15$167
Brimonidine Tartrate13$109
Doxycycline Monohydrate12$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$32$33,26230 claims
Bausch & Lomb Americas Inc.Xiidra$14$9,54912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 749 optometrist providers in Alabama.

Other optometrist in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →